The Directors of Scancell are pleased to announce that on 19 December 2008, the Company issued 73,333 new ordinary shares of 1p each in lieu of advisory fees relating to the admission of the Company onto the PLUS-quoted market at a price of 60 pence per share.
The trading of the new ordinary shares on PLUS is expected to commence on 22 December 2008.
Following the issue of shares as detailed above the total number of ordinary shares in issue as at 19 December 2008 will be 10,275,551 ordinary shares. The total Directors' Shareholding as a result of the Issue of Equity is 2,627,892 ordinary shares representing 25.57% of the current issued share capital.
The Directors of the issuer accept responsibility for this announcement.
Scancell Holdings PLC (LON:SCLP) CEO Cliff Holloway caught up with Proactive London's Andrew Scott following the announcement they'd raised £3.88mln via a placing with a single new investor to help fund the progression of its lead cancer asset into clinical trials.
The Vulpes Life Sciences Fund will now have a 16.67% stake in the company when the shares are issued next Monday.
Thu, 13 Jun 2019 09:53:00
“At Vulpes we are always searching for overlooked companies that have the ability to make significant advances in medical science, with a view to supporting their development over the long term. We believe Scancell fulfil these criteria perfectly.”
Thu, 13 Jun 2019 06:31:00
Here we take a closer look at Scancell, which is at the vanguard of immuno-oncology
Mon, 20 May 2019 09:51:00
Sign up to our newsletter to stay up to date with Scancell